一氧化氮负载的纳米材料作为化疗药物载体逆转肿瘤多药耐药性的研究进展  

Nitric oxide-releasing drug delivery systems for overcoming drug resistance in chemotherapy

作　　者：陈敏[1] 吴梅岭 范颖[1] 伍雯 CHEN Min;WU Mei-ling;FAN Ying;WU Wen(Chongqing Key Laboratory of Natural Product Synthesis and Drug Research,School of Pharmaceutical Sciences,Chongqing University,Chongqing 401331,China)

机构地区：[1]重庆大学药学院重庆市天然产物全合成与创新药物研究重点实验室,重庆401331

出　　处：《药学学报》2018年第10期1630-1636,共7页Acta Pharmaceutica Sinica

基　　金：国家自然科学基金资助项目(81741169);中央高校基本科研业务资助项目(0903005203498;2018CDYXYX0027)

摘　　要：化学治疗药物与放射治疗等治疗方法对攻克癌症做出了重大贡献,可肿瘤细胞的多药耐药(multidrug resistance,MDR)仍是实现高效化疗的主要障碍。近期的研究表明一氧化氮(nitricoxide,NO)可以克服MDR,不同于其他具有潜在毒性的化疗增敏剂,NO是内源性分子,具有良好的生物相容性。这一特性使其有望成为高效低毒的肿瘤治疗策略。负载NO的纳米载药系统不仅有利于多种治疗药物的递送,而且有助于增加肿瘤细胞对药物的敏感性,克服MDR。因此,本文将综述利用负载NO的纳米材料输送抗癌药物以逆转肿瘤耐药性的研究进展及相关机制。Chemotherapeutic agents along with other treatments, such as chemotherapy and radiotherapy, have made significant contributions to cancer therapy, however multidrug resistance（MDR） in tumor remains an important developmental barrier to efficient chemotherapy. In recent research, there is increasing evidence that nitric oxide（NO） has the potential to overcome MDR. Unlike other chemosensitizers that ameliorate MDR but are potentially toxic, NO is endogenous and biocompatible molecule, which makes it even more promising as a cancer therapeutic. Nanoparticle-based drug delivery systems not only facilitate the delivery of multiple therapeutic agents, but also promote the avoidance of MDR, which are promising to both efficient delivery of NO and anti-cancer drugs in combination. Therefore, this review will discuss the mechanisms how NO reverse MDR and the recent advances in the application of NO functionalized nanoparticles for anticancer drug delivery.

关 键 词：肿瘤多药耐药性 一氧化氮供体 纳米粒 化疗增敏 药物输送 

分 类 号：R943[医药卫生—药剂学]